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Abstract: Plants have been used for centuries to treat several illnesses. The Plectranthus genus has a
vast variety of species that has allowed the isolation of cytotoxic compounds with notable activities.
The abietane diterpenes 6,7-dehydroroyleanone (DeRoy, 1), 7α-acetoxy-6β-hydroxyroyleanone (Roy,
2), and Parvifloron D (ParvD, 3) were obtained from Plectranthus spp. and showed promising
biological activities, such as cytotoxicity. The inhibitory effects of the different natural abietanes (1-3)
were compared in MFC7, SkBr3, and SUM159 cell lines, as well as SUM159 grown in cancer stem
cell-inducing conditions. Based on the royleanones’ bioactivity, the derivatives RoyBz (4), RoyBzCl
(5), RoyPr2 (6), and DihydroxyRoy (7), previously obtained from 2, were selected for further studies.
Protein kinases C (PKCs) are involved in several carcinogenic processes. Thus, PKCs are potential
targets for cancer therapy. To date, the portfolio of available PKC modulators remains very limited
due to the difficulty of designing isozyme-selective PKC modulators. As such, molecular docking
was used to evaluate royleanones 1-6 as predicted isozyme-selective PKC binders. Subtle changes in
the binding site of each PKC isoform change the predicted interaction profiles of the ligands. Subtle
changes in royleanone substitution patterns, such as a double substitution only with non-substituted
phenyls, or hydroxybenzoate at position four that flips the binding mode of ParvD (3), can increase
the predicted interactions in certain PKC subtypes.
Keywords: Plectranthus; royleanones; hemi-synthesis; PKC activity; isozyme-selectivity;
molecular interactions
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1. Introduction
Although many commercially available chemotherapeutic agents are plant-derived products
(e.g., paclitaxel, vincristine, irinotecan), some may induce resistance and toxic effects that can
compromise therapy success and consequent patient recovery [1]. Therefore, the search for novel
effective drugs with suppressed or lower toxicity on normal cells is still demanded [1], as well as the
elucidation of their effect on the modulation of cell death mechanisms and consequent affected targets,
is also very important [2,3].
The Plectranthus genus has a vast variety of species scattered throughout tropical Africa, Asia, and
Australia, and is known for its broad spectrum of activities [4,5]. Several species have already been
screened for the presence of cytotoxic compounds with notable activities [3,6,7], such as secondary
metabolites of diterpenes belonging to the abietane class [8–10]. Royleanones are bioactive compounds
with a tricyclic skeleton characteristic of the abietane class and can possess phenolic and quinonic
moieties [11]. 6,7-dehydroroyleanone (DeRoy, 1, Figure 1) was identified as the main component of the P.
madagascariensis (Pers.) Benth essential oil [12]. DeRoy (1) showed promising antioxidant, antimicrobial,
and cytotoxic activity [3,13]. In the same way, the compound 7α-acetoxy-6β-hydroxyroyleanone (Roy, 2,
Figure 1) obtained from P. grandidentatus exhibited cytotoxicity at low concentrations against different
types of human cancer cell lines (MCF-7, NCI-H460, SF-268, TK-10, UACC-62) [9]. Parvifloron D
(ParvD, 3, Figure 1) is the main phytochemical constituent of P. ecklonii with cytotoxic activity against
several human tumor cells and an apoptotic inducer in leukemia cells. [14].
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reported protein kinase Cδ (PKCδ) selective activator [15] and was obtained by semi-synthesis from 
compound 2 [16]. In fact, a recent study reported that 4 potently inhibits the proliferation of colon 
cancer cells through a PKCδ-dependent mitochondrial apoptotic pathway involving caspase-3 
activation [15]. These results have suggested that abietanes can originate a new class of 
PKCδ-selective modulators with potential application for colon cancer therapy. Other interesting 
derivatives prepared using 2 as a starting material are 7α-acetoxy-6β-(4-chloro) 
benzoyloxy-12-O-(4-chloro)benzoylroyleanone (RoyBzCl, 5), 
7α-acetoxy-6β-propanoyloxi-12-O-propanoylroyleanone (RoyPr2, 6), and 6,7-dihydroxyroyleanone 
(DihydroxyRoy, 7) (Figure 2). Nonetheless, to date, the effect of 4, 5, and 6 as PKC modulators has 
not been investigated. 
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hese natural royleanones can be interesting leads for drug development by enhancing cytotoxic
properties. They contain acidic hydroxyl groups suitable for derivatization. Furthermore, the patented
diterpene 6β-benzoyloxy-12-O-benzoylroyleano e (RoyBz, 4, Figure 2) is the first reported protein
kinase Cδ (PKCδ) selective activator [15] and was obtained by semi-synthesis from compound 2 [16].
In fact, a recent study reported that 4 potently inhibits the roliferation of colon cancer cells through a
PKCδ-dependent mitochondrial apoptotic pathway involving caspase-3 activatio [15]. These results
have suggested that abietanes can originate a new class of PKCδ-selective modulators with potential
application for colon cancer therapy. Other interesti g derivatives prepared using 2 as a starti
material are 7α-acetoxy-6β-(4-chloro) benzoyloxy-12-O-(4-chloro)benzoylroyleanone (RoyBzCl, 5),
7α-acetoxy-6β-propanoyl xi-12-O-propanoylroyleanone (RoyPr2, 6), and 6,7-dihydroxyroyleanone
(DihydroxyRoy, 7) (Figure 2). Nonetheless, to date, the effect of 4, 5, and 6 as PKC modulators has not
been investigated.
PKC is an attractive target for cancer therapy as recently demonstrated by pre-clinical and clinical
data [17]. PKC is a large family of serine-threonine kinases whose isozymes share a conserved
N-terminal regulatory region that comprises C1 and C2 domains, and a C-terminal catalytic region
responsible for ATP binding and phosphotransferase activity [17,18]. To date, 10 isozymes of PKC
have been identified and can be grouped into three subfamilies: Classical (α, βI, βII, and γ), novel
(δ, ε, η, and θ), and atypical PKCs (ζ and λ\ι) [17,19]. These isozymes differ in structure, function,
and biochemical properties. The PKC family has been intimately associated with the development
and progression of cancer and plays a major role in numerous metabolic and signaling pathways
associated with proliferation, migration, differentiation, apoptosis, invasion, tumorigenesis, and
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The major challenge from a pharmacological standpoint for the design of isozyme-selective
PKC modulators is that PKCs are highly related among them, as well as to other structurally related
kinases [20,21]. Furthermore, PKC isozymes may exhibit overlapping as well as opposite functions
in cancer development [21]. PKCα seems to be related to malignant glioma cells’ growth [22]. PKCβ
isoforms have been associated with progression of breast cancer [23], colon cancer [24], and prostate
cancer [25]. Moreover, PKCι is implicated in the progression of lung cancer [26] and ovarian tumor [27].
An overexpression of PKCε was observed in head and neck squamous cell carcinoma [28], and human
non-small cell lung cancer [29]. Increased activity of PKCζ was found to promote tumorigenesis in
breast [30] and pancreatic [31] cancer. PKCζ also seems to function as a tumor suppressor in prostate
cancer [32].
Human pluripotent stem (hPS) cells possess the ability of self-renewal, a process heavily supported
by the existence of signaling pathways such as those of PKC, among others [33]. As such, cancer
stem cells (CSCs) have tumor-initiating properties and have been identified in a variety of carcinomas
including breast cancer [34]. In fact, these are responsible for cancer-related phenomena such as tumor
growth, recurrence, and metastasis [34]. Additionally, although some chemicals or radiations are
effective in eliminating the bulk of cancer cells, the majority fail to eliminate the CSC subpopulation
leading to the generation of new tumors [34]. Therefore, recent research has focused on finding
effective treatments targeting these cells. PKC subtypes such as PKCα are a central target when
addressing toxicity for breast cancer stem cells and their expression is usually associated with
aggressive triple-negative breast cancers. In this way, their inhibition is crucial when targeting breast
CSCs [34].
PKCs are activated by endogenous calcium, diacylglycerol, phospholipids, and/or tumor-
promoting phorbol esters, binding in the C1 domain. Other structurally diverse activators isolated from
different organisms have been described [35]. It is generally accepted that most of the PKC activators
bind to the regulatory domain [17,35]. On the other hand, kinase inhibitors are ATP-competitive small
molecules that bind to the kinase domain (ATP binding site) of the PKC isozymes [36]. Currently,
several classes of PKC inhibitors exist at different levels of development and some of them have reached
clinical trials for the treatment of different cancers, such as bryostatin 1, curcumin, staurosporine,
midostaurin, and sotrastaurin [35,36]. Unfortunately, to date, the portfolio of available PKC modulators
remains very limited and most of the small molecules identified lack specificity among isoforms of the
PKC family or even with other kinases unrelated to PKC, which is not suitable for clinical use [17].
Due to this, the search for more selective and potent ATP-competitive inhibitors remains a promising
strategy for the future of anticancer treatment.
To our knowledge, royleanones have never been evaluated as PKC inhibitors. Herein, molecular
docking studies were performed for compounds 1-6 in order to clarify the molecular interaction to the
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kinase domain of PKC isoforms. Molecular docking techniques are valuable because they can provide
initial information on possible binding sites, binding energies, and specific ligand–residue interactions.
These results may help in the selection of which derivatives should be synthesized for structure–activity
relationships in the different PKC isoforms, also providing clues towards their specificity and design.
The activity towards breast cancer cell lines of different malignancy for the natural abietanes 1 to 3
isolated from Plectranthus spp. was also evaluated in vitro.
2. Results
2.1. MTT Breast Cancer
The inhibitory effects of the different natural royleanones (1-3) were compared in MFC-7, SkBr3,
SUM159, and SUM159 grown in CSC-inducing conditions. CSC represents the subpopulation of cancer
cells that is responsible for metastasis. Due to their morphological characteristics of growth in spheres,
they are referred to as SUM159 spheres. Three-dimensional in vitro models can be considered as an
intermediate model between in vitro cancer cell line cultures and in vivo tumor. Different cancer cell
lines were used aiming to assess which of the cell development phases is most affected by the action of
each abietane compound.
The results showed that increased concentrations of abietanes reduced cell viability (Figure 3).
Overall, although Roy (2) and ParvD (3) tend to inhibit MCF-7, SkBr3, and SUM159 cell viability, it
was shown to be less effective against the most aggressive type of cells, the cancer stem cells SUM159
sphere. DeRoy (1) showed the highest inhibitory effect on SUM159 spheres, thus indicating its potential
to significantly decrease the number of viable CSC cells.
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Figure 3. Cytotoxicity activity (MTT assay) on MCF-7 (hormone-positive breast cancer cells), SkBr3
Her-positive, SUM159 triple-negative, and SUM159 spheres. Statistical significance between marked
groups: ** p < 0.01, *** p < 0.001, **** p < 0.0001.
2.2. Docking Results
The Protein DataBank (PDB, [37]) had the following available protein crystal structures: θ: 5F9E;
ι: 3ZH8, 3AW8, 3A8X (only 3ZH8 has a co-crystallized inhibitor); α: 4RA4; and βII: 2I0E. There are
crystal structures of other isomorphs; however, structures 1YRK and 2YUU (δ), and 2WH0 (ε) do not
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contain the catalytic domain, while no structure of the ζ isoform is available. From the percent identity
matrix (Table 1), isomorph θ seems to be the most similar to isoform δ. Based on these results, we took
structures 4RA4 for isoform α, 3ZH8 for isoform ι as an approximation to ζ, and 5F9E for isoform θ
(and as an approximation to isoform δ). Isoform α was taken as an approximation to isoform ε. 1PTR
was taken for isoform δ.
Table 1. Percent identity matrix from the sequence alignment of protein isoforms.
Uniprot, Isoform ζ I δ θ ε α β
sp|P41743|KPCI_HUMAN, ζ 100 72.81 36.82 36.86 44.78 43.57 43.48
sp|P41743|KPCI_HUMAN, ι 72.81 100 36.14 36.52 43.91 45.36 44.21
sp|Q05655|KPCD_HUMAN, δ 36.82 36.14 100 64.89 43.88 47.61 48.99
sp|Q04759|KPCT_HUMAN, θ 36.86 36.52 64.89 100 43.31 48.51 47.64
sp|Q02156|KPCE_HUMAN, ε 44.78 43.91 43.88 43.31 100 52.9 53.14
sp|P17252|KPCA_HUMAN, α 43.57 45.36 47.61 48.51 52.9 100 79.01
sp|P05771|KPCB_HUMAN, β 43.48 44.21 48.99 47.64 53.14 79.01 100
The results from the docking runs of all programs, proteins, and ligands (Table 2) showed that
ParvD (3), Roy (2), and DeRoy (1) tended to have calculated docking scores close to those of the
co-crystallized ligands (i.e., known binders) for all five isoforms studied. The MMGBSA results only
showed a favorable calculated docking scores for 1 in isoforms θ, β, and ι but not in α. These results
for the interaction can be compared to experimental observations showing that compounds 3 and 1 are
the strongest inhibitors for all cell types. The weakest docking scores correspond to the compounds
docked into the PKCδ isoform.
From the data presented in Tables 1–5, we can explain the general trends in the docking scores
of royleanones to different isoforms of PKC. Docking calculations report docking scores of up to
−9.9 kcal/mol for 1 and 3. From the intermolecular interaction analysis (Table 3), 1 interacts with 11
amino acid residues in a hydrophobic manner. Kinases share overlapping substrate recognition patterns
but specific hydrophobic binding pockets for recognizing bulky hydrophobic residues upstream of
the catalytic Ser/Thr distinguish atypical PKCs from other kinases, and this may provide specificity.
In addition, although reportedly forming a hydrophobic interaction with the conserved Lys 371,
we cannot rule out the possibility for hydrogen bond formation as well, analogous to the case in the α
isoform (with a corresponding conserved residue Lys 368). This actually is significantly different to
compound 2, as 1 is capable of forming this additional interaction. Moreover, a significant difference in
the logP values (Table 5) between 2 and 1 makes the latter more favorable for the local hydrophilic
environment of the binding site (Thr 404, Lys 371, Met 473, and Met 420, if considered as amphipathic),
rather than the more lipophilic 2. In addition, if we compare the percent of exposed surface area of the
docked conformations in the PKC α isoform, 1 is more “buried”, and therefore more prone to keeping
the bound conformation than 2. Regarding 5 and 6, both have similar binding patterns to compounds 2
and 1. However, the Autodock docking score values are contradictory with respect to the experimental
inhibition results. Therefore, the explanation may be found in the compounds’ properties. 5 has a
similar logP value and ratio of the exposed surface as 1, while 5 has the highest logP value and a
more exposed surface. This is probably the reason for the lower interaction score: The compound is
too nonpolar and less buried in the binding site, which contributes to an easier unbinding process.
Figure 4 shows the difference in the exposed surface area for 1 and 5.
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Table 2. Calculated docking scores for compounds against PKC isoforms. All values in kcal/mol.
Compound 5f9e (Isoform θ) 2i0e (Isoform βII) 3zh8 (Isoform ι) 4ra4 (Isoform α) 1ptr (Isoform δ)
Vina GlideXP MMGBSA Vina
Glide
XP MMGBSA Vina
Glide
XP MMGBSA Vina
Glide
XP MMGBSA Vina
Glide
XP MMGBSA
PMA −7.4 −8.0 −4.84 −40.13 −7.2 −6.4 −4.7 −4.41 −42.12
ARA −6.3 −7.8 −1.00 −40.95 −6.5 −5.6 −4.4 −1.85 −18.56
5VS1001
(5f9e co-cryst.) −10.5 −7.2 −40.48
PDS 902
(2i0e co-cryst.) –11.0 −10.02 −56.23
C581582
(3zh8 co-cryst.) −9.9 −8.0 −58.56
3KZ701
(4ra4 co-cryst.) −10.4 −10.0 0
PRB3
(1ptr co-cryst.) −6.3 −4.25 −27.00
1 (DeRoy) –9.3 −5.8 −44.29 −12.0 −6.21 −30.81 −8.4 −5.6 −36.23 −8.4 −6.7 0 −6.2 −4.13 −29.39
2 (Roy) –9 −10.4 −8.8 −8 −6.7
3 (ParvD) –9.8 −2.0 −12.0 −5.84 −9.8 −6.91 −9.3 −4.84 −8.4 −4.68
4 (RoyBz) –9.3 −9.4 −9.0 −8.7 −6.9
5 (RoyBzCl) –8.8 −9.8 −9.4 −8.4 −6.7
6 (RoyPr2) –8.7 −7.9 −7.4 −7.5 −6.3
7 (DihidroxyRoy) –8.3 −10.5 −8.7 −7.6 −7.9
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Table 3. PKC isoform binding site amino acids and corresponding interactions.
Compounds PKC Isoform
α βI ι θ
DeRoy (1)
Met 417 (L), Ala 480 (L),
Met 470 (L), Lys 368 (H),
Val 353 (L), Leu 345 (L)
Met 473 (L), Ala 483 (L), Phe
485 (L), Leu 394 (L), Phe 353
(L), Val 356 (L), Lys 371 (L),
Phe 418 (L), Met 420 (L), Ala
369 (L), Leu 348 (L)
Leu 376 (L), Thr 386 (R),
Val 307 (L), Phe 297 (L),
Ile 323 (L), Lys 274 (L),
Val 259 (L), Ile 251 (L)
Leu 511 (L), Ala 521 (L),
Met 458 (L), Lys 409 (H),
Val 394 (H), Phe 391 (R)
Roy (2)
Val 420 (H), Lys 368 (L),
Ala 366 (L), Met 417 (L),
Val 353 (L), Leu 345 (H, L)
Met 473 (L), Ala 483 (L), Phe
353 (L), Met 420 (L),
Lys 371 (L), Val 356 (L)
Asp 373 (H), Ile 323 (L)
Leu 511 (L), Asn 509 (L),
Ala 521 (L), Met 458 (L),
Lys 409 (L), Val 394 (L),
Leu 386 (L)
ParvD (3)
Met 470 (L), Val 353 (L),
Ala 366 (L), Leu 345 (L),
Met 417 (R, L), Lys 368 (L),
Leu 391 (L), Ala 480 (L)
Met 473 (L), Tyr 422 (L), Leu
348 (L), Val 356 (L), Ala 483
(L), Ala 369 (L), Asn 471 (H),
Phe 485 (L), Leu 394 (L),
Lys 371 (L)
Ile 251 (L), Val 259 (L),
Leu 376 (L), Tyr 325 (H),
Val 259 (L), Thr 386 (L),
Lys 274 (L), Ile 323 (L),
Val 307 (L), Phe 297 (L)
Leu 511 (L), Ala 521 (L),
Met 458 (L), Ala 407 (L),
Val 394 (L), Phe 391 (L)
RoyBz (4)
Asp 424 (H), Ala 366 (L),
Val 353 (L), Met 417 (L),
Lys 368 (L), Ala 480 (L)
Leu 348 (L), Met 473 (L), Val
356 (L), Phe 353 (L), Lys 371
(L), Met 420 (L), Ala 483 (L)
Phe 333 (L, R), Asp 330
(H), Ile 251 (L), Leu 376
(L), Val 259 (L), Thr 386
(R), Ala 272 (L), Ile 323
(L), Val 307 (L)
Gly 464 (L), Phe 391 (L),
Val 394 (L), Ala 407 (L),
Met 458 (L), Ala 521 (L),
Asp 522 (L), Lys 409 (H)
RoyBzCl (5)
Asp 424 (H), Gly 423 (L),
Met 343 (R, L), Val 353 (L),
Phe 350 (L), Lys 368 (L),
Met 417 (L), Ala 480 (L)
Met 473 (L), Ala (483), Leu
394 (L), Met 420 (R, L), Lys
371 (L), Val 356 (L), Phe 353
(L), Leu 348 (L)
Phe 333 (R), Asp 330 (H),
Thr 386 (R), Val 307 (L),
Ile 323 (R), Ala 272 (R),
Val 259 (R, L), Ile 251 (L),
Arg 253 (R, L)
Leu 511 (L), Ala 521 (L),
Lys 506 (L), Phe 391 (R),
Val 394 (L), Leu 386 (R),
Tyr 460 (L)
RoyPr2 (6)
Asp 424 (H), Met 470 (L),
Val 420 (L), Met 417 (L),
Ala 366 (L), Val 353 (L)
Ala 483 (L), Phe 383 (L), Lys
371 (L), Val 356 (L),
Leu 348 (L)
Thr 386 (H), Leu 376 (L),
Ile 251 (L), Val 259 (L),
Ala 257 (L)
Leu 511 (L), Ala 521 (L),
Met 458 (L), Lys 409 (H,
L), Ala 407 (L), Val 394
(L), Phe 391 (L)
DihydroxyRoy (7)
Met 470 (L), Val 420 (H),
Met 417 (L), Lys 368 (L),
Leu 345 (H, L)
Phe 353 (L), Leu 348 (L), Val
356 (L), Lys 371 (L), Met 420
(R, L), Leu 394 (L), Phe 485
(L), Ala 483 (L)
Asp 373, Val 259, Lys 274,
Ala 272, Ile 323
Leu 511 (L), Ala 521 (L),
Phe 523 (L), Leu 432 (L),
Met 458 (L), Lys 409 (L),
Val 394 (L), Leu 386 (L),
Phe 391 (R)
H—Hydrophobic interaction; L—Hydrophilic interaction; R—aromatic interaction.
Table 4. Corresponding amino acid residues in different PKC isoforms.
PKCα PKC βI PKCι PKCθ
Met 470 Met 473 Leu 376 Leu 511
Ala 480 Ala 483 Thr 386 Ala 521
Thr 401 Thr 404 Val 307 Thr 442
Met 417 Met 420 Ile 323 Met 458
Lys 368 Lys 371 Lys 274 Lys 409
Val 353 Val 356 Val 259 Val 394
Leu 345 Leu 348 Ile 251 Leu 386
Table 5. Compound octanol/water partition (logP) values and solvent-accessible surface area for docked
poses in PKCα isoform.
Compound Total Solvent AccessibleArea (Å2)
Solved Exposed Area in
Docked Pose (Å2) Exposed Surface Ratio % logP
DeRoy (1) 268.47 142.36 53.02 4.53
Roy (2) 318.47 209.29 65.71 2.65
ParvD (3) 171.75 355.37 48.12 5.64
RoyBz (4) 469.79 260.01 55.35 7.88
RoyBzCl (5) 504.92 323.30 64.03 8.8
RoyPr2 (6) 403.77 207.97 51.50 4.87
DihidroxyRoy (7) 285.37 165.58 58.02 2.52
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Compound 3 shows the best docking score towards the PKC βII isoform (−9.9 kcal/mol), however,
without selectivity towards other isoforms. The high predicted affinity may be explained by the
formation of more hydrophobic interactions with binding site amino acids than in the case of 1 and 2.
In addition, 3 has a higher logP value, and the ratio between the total solvent-exposed and docked
conformation solvent-exposed surface is the lowest in the case of 3, which indicates a slower unbinding
process. Both properties are in favor of a higher predicted affinity towards any of the PKC isoforms.
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The binding site of PKCδ can be seen to be aligned onto PKCι (Figure 5). ParvD (3), DeRoy (1),
and RoyBz (4) are moderately sized compounds compared to the others in this series, which may allow
for a better fit in the different PKC binding sites, though PKCδ has a smaller binding site as compared
to the other isoforms.
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3. Discussion
Even though the mechanism of roylaneone compound inhibition of cancer cells is not yet
determined as exclusively through inhibition or activation (4 activates PKCδ [15]) of specific PKC
isoforms, ParvD (3) has the best calculated interaction profile of compounds 1-3, given its good
interactions of the core structure and substituents with Val326 in the PKC binding site, as well as
experimental inhibition against all cell types, including the most aggressive form. Structure 3ZH8,
representing isoform PKCι, appears to best reproduce experimental trends, and therefore, may provide
clues for compound design. Substitution groups, such as hydroxybenzoate on position 4 of the
royleanone core, can provide a better docked binding pose. In addition, polar groups at the mouth
of the binding site are in close proximity to the 1,1 dimethyl groups. A possible route for further
modification may be decorating or substituting these 1,1-methyl groups with polar functional groups
able to make hydrogen bonds with these residues on PKC, such as –OH or –NH3, as well as improving
the compounds’ logP value.
Clues on PKC isoform modulation may give information on the specificity towards each isoform
based on the structure of their different biding sites, as well as on useful probe compounds, such as
royleanones. Even if it may be difficult to pick up differences in the binding sites of PKC isoforms,
this is indeed possible. Selective thieno[2,3-d]pyrimidine-based chemical inhibitors of atypical PKCs
have been reported [38], and the region of hydrophobic residues in the binding site upstream from
the catalytic Lys/Thr provides this specificity for compounds with bulky hydrophobic groups. The
conserved Lys 371, on the other hand, provides a binding partner in nearly all isoforms. Atypical PKCs
can tolerate the Lys -> Trp mutation, whereas other PKCs cannot [39].
Compounds in phase I or phase II clinical trials targeting classical PKC isoforms were not
successful [31], but recent studies implicate that mainly atypical and novel PKC enzymes regulate
oncogenic signaling pathways in pancreatic cancer. These subgroups converge signaling induced by
mutant K-Ras, inflammatory cytokines, and growth factors. Approaches to compound design for
novel PKCs and atypical PKCs may include allosteric inhibitors and ATP competitive inhibitors. The
royleanone core and derivatives are interesting for further research on their different interactions with
different PKC isoforms, pancreatic cancer, and breast cancer cell lines with an emphasis on breast CSC,
which are attractive target cells as these are the cells with the highest metastatic potential.
4. Materials and Methods
4.1. Compounds
Compounds 1, 2, and 3 were isolated from Plectranthus spp. DeRoy (1) was obtained from the
essential oil through the hydrodistillation of leaves and steams of P. masdascariensis (Pers.) Benth. in a
Clevenger-apparatus, according to C. Garcia et al., 2018 [3]. Acetonic extraction and isolation of Roy (2)
from aerial parts of P. grandidentatus Gürke, was adapted from the procedure described on Bernardes
C.E.S. et al., 2018 [40]. ParvD (3) was isolated from the acetonic extract of the whole plant P. ecklonii
Benth, according to Simões et al., 2010 [41]. On the other hand, RoyBz (4), RoyBzCl (5), RoyPr2 (6), and
DihydroxyRoy (7) are derivatives previously obtained from 2 [42]. All compounds were used pure
and their structures were confirmed by spectroscopic means and compared to literature data.
DeRoy (1): Orange-red needles, 1H NMR (CDCl3, 300 MHz, ppm): δ 7.34 (1H, s, OH-12), 6.81
(1H, dd, J = 9.7, 3.2 Hz, H-7), 6.46 (1H, dd, J = 9.7, 3.2 Hz, H-6), 3.16 (1H, hept, J = 7.1 Hz, H-15), 2.88
(1H, dt, J = 13.3 Hz, H-1β), 2.13 (1H, t, J = 3.2 Hz, H-5α), 1.63–1.60 (1H, t, H-2α), 1.52–1.50 (1H, t, H-2β),
1.47–1.46 (1H, m, H-3β), 1.42 (1H, d, J = 4.2 Hz, H-1α), 1.23 (1H, s, H-3α), 1.22 (Me-16, overlapped
signal), 1.20 (Me-17, overlapped signal), 1.03 (3H, s, Me-20), 1.01(3H, s, Me-18), 0.98 (3H, s, Me-19).
13C NMR (CDCl3, 75 MHz, ppm): δ; 186.20 (C-14), 183.58 (C-11), 151.34 (C-12), 140.64 (C-9), 139.8
(C-6), 138.6 (C-8), 122.72 (C-13), 121.33 (C-7), 52.23 (C-5), 40.64 (C-4), 39.38 (C-3), 35.28 (C-1), 33.40
(C-10), 32.74 (C-19), 24.21 (C-18), 22.94 (C-15), 20.14 (C-17), 19.95 (C-16), 18.81 (C-2), 15.31 (C-20).
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Roy (2): Yellow quadrangular plates, 1H-NMR (CDCl3, 300 MHz, ppm): δ 7.22 (1H, s, 12-OH),
5.66 (1H, dd, J = 2.2, 0.7 Hz, H-7β), 4.31 (1H, s, H-6α), 3.16 (1H, sept, J = 7.1 Hz, H-15), 2.63 (1H, d,
J = 12.8 Hz, H-1β), 2.04 (3H, s, Me-7α-OAc), 1.89–1.78 (1H, m, H-2β), 1.61 (3H, s, Me-20), 1.55–1.46 (2H,
m, H-2α and H-3β, overlapped signal), 1.33 (1H, s, H-5α), 1.23 (3H, s, Me-19, overlapped signal), 1.22
(3H, s, Me-17, overlapped signal), 1.21 (1H, s, H-3α, overlapped signal), 1.20 (3H, s, Me-16, overlapped
signal), 1.18 (1H, s, H-1α, overlapped signal), 0.94 (3H, s, Me-18). 13C-NMR (CDCl3, 75 MHz, ppm):
δ 185.91 (C11), 183.40 (C14), 169.83 (7α-COCH3), 151.04 (C12), 150.04 (C9), 137.19 (C8), 124.76 (C13),
68.86 (C7), 67.06 (C6), 49.86 (C5), 42.39 (C3), 38.75 (C10), 38.55 (C1), 33.80 (C18), 24.28 (C15), 23.94 (C19),
21.60 (C20), 21.08 (7α-COCH3), 19.97 (C16), 19.84 (C17), 19.10 (C2).
ParvD (3): Orange powder, 1H-NMR (CDCl3, 300 MHz, ppm): δ 7.93 (2H, d, H-2’ and H-6’), 6.96
(1H, d, J = 6.8 Hz, H-14), 6.88 (2H, d, H-3’ and H-5), 6.79 (1H, d, J = 6.9 Hz, H-7), 6.41 (1H, s, J = 12.5
Hz, H-6), 5.59 (1H, tt, J = 4.4 Hz, H-2β), 3.76 (1H, ddd, J = 11.4 Hz, H-1β), 3.15 (1H, m, H-15), 2.15 (1H,
ddd, J = 4.4 Hz, H-3β), 1.74 (1H, dd, J = 13.0 Hz, H-1α), 1.64 (3H, s, Me-20), 1.56 (1H, dd, J = 11.4 Hz,
H-3α), 1.42 (3H, s, Me-19), 1.29 (3H, s, Me-18), 1.18 (3H, d, J = 0.8 Hz, Me-16), 1.16 (3H, d, J = 2.4 Hz,
Me-17). 13C-NMR (CDCl3, 75 MHz, ppm): δ 178.24 (C12), 166.18 (C7’), 164.84 (C5), 160.58 (C4’), 146.50
(C11), 141.61 (C13), 139.30 (C7), 133.57 (C14), 131.89 (C2’ and C6’), 127.45 (C8), 127.17 (C9), 122.43 (C1’),
118.69 (C6), 115.23 (C3’ and C5’), 67.87 (C2), 45.06 (C3), 43.91 (C10), 38.58 (C4), 38.37 (C1), 33.03 (C18),
30.58 (C19), 26.52 (C15), 25.52 (C20), 21.84 (C16), 21.63 (C17)
RoyBz (4): Yellow quadrangular plates (EtOAc–n-pentane), 1H-NMR (CDCl3, 400 MHz, ppm):
δ 8.15 (2H, dt, J2’,3’ = 7.6 Hz, J2’,4’ = 2.0 Hz, H–2’ and H–6’, 6–OBz), 7.99 (2H, dt, J2’,3’ = 7.2 Hz, J2’,4’
= 1.2 Hz, H-2’ and H–6’, 12–OBz), 7.69–7.40 (6H, complex signal, H–3’, H–4’, H–5’, 6– and 12–OBz),
5.90 (1H, dd, J7β,6α = 2.0 Hz, J7β,5α = 0.9 Hz, Hβ–7), 5.77 (1H, dd, J6α,7β = 2.0 Hz, J6α,5α = 1.6 Hz,
Hα–6), 3.17 (1H, sept, J15,16(17) = 7.1 Hz, H–15), ~2.58 (1H, Hβ–1, overlapped signal), 2.10 (3H, s,
OAc-7α), ~1.78 (1H, Hβ–2, overlapped signal), 1.77 (3H, s, Me-20), 1.69 (1H, br d, J5α,6α = 1.6 Hz,
Hα–5), 1.58 (1H, Hα–2, overlapped signal), 1.49 (1H, ddd, J3β,3α = 13.2 Hz, J3β,2α = 3.6 Hz, J3β,2β
= 2.8 Hz, Hβ–3), 1.29 (1H, td, J1α,1β = J1α,2β = 13.2 Hz, J1α,2α = 3.8 Hz, Hα–1), ~1.38 (1H, Hα–3,
overlapped signal), 1.21 (3H, d, J17,15 = 7.1 Hz, Me-17), 1.19 (3H, d, J16,15 = 7.1 Hz, Me-16), 1.06 (3H,
s, Me-18), 0.99 (3H, s, Me-19). 13C NMR (CDCl3, 100 MHz, ppm): δ 185.33 (C-14, s); 180.00 (C-11, s);
168.13 (7α–OAc, s); 165.33 (C-7’, 6–OBz, s); 164.00 (C-7’, 12–OBz, s); 152.50 (C-9, s); 150.00 (C-12, s);
140.00 (C-13, s); 136.20 (C-8, s); 134.30 (C-4’, 12–OBz, d); 133.22 (C-4’, 6–OBz, s); 130.51 (C-3’ and C-5’,
12–OBz, d); 129.87 (C-3’ and C-5’, 6–OBz, d); 129.71 (C-1’, 6– OBz, s); 128.81 (C-2’ and C-6’, 12–OBz, d);
128.47 (C-2’ and C-6’, 6–OBz, d); 127.91 (C- 1’, 12–OBz, s); 68.43 (C-6, d); 65.25 (C-7, d); 49.31 (C-5, d);
42.48 (C-3, t); 38.77 (C-10, s); 38.37 (C-1, t); 33.76 (C-4, s); 33.33 (C-18, q); 25.16 (C-15, d); 23.21 (C-19, q);
22.20 (C-20, q); 20.84 (7α- OAc, q); 20.36 (C-16, q); 20.00 (C-17, q); 18.83 (C-2, t);
RoyBzCl (5): Yellow amorphous powder, 1H-NMR (CDCl3, 400 MHz, ppm): δ 8.08 (2H, d, Jo = 8.6
Hz, H–2’ and H–6’, 12–OBzCl), 7.92 (2H, d, Jo = 8.6 Hz, H–2’ and H–6’, 6–OBzCl), 7.51 (2H, d, Jo = 8.6
Hz, H–3’ and H–5’, 12–OBzCl), 7.39 (2H, d, Jo = 8.6 Hz, H–3’ and H–5’, 6–OBzCl), 5.88 (1H, d, J7β,6α =
1.6 Hz, Hβ–7), 5.76 (1H, t, J6α,7β = J6α,5α = 1.6 Hz, Hα–6), 3.17 (1H, sept, J 15,16(17) = 7.0 Hz, H–15),
2.58 (1H, Hβ–1, overlapped signal), 2.10 (3H, s, 7α–OAc), 1.79 (1H, qt, J2β,1α = J2β,2α = J2β,3α = 14.0
Hz, J2β,1β = J2β,3β = 3.7 Hz, Hβ–2), 1.74 (3H, s, Me-20), 1.70 (1H, d, J5α,6α = 1.6 Hz, Hα–5), 1.60 (1H,
dquint, J2α,2β = 14.0 Hz, J2α,1α = J2α,1β = J2α,3α = J2α,3β = 3.6 Hz, Hα–2); 1.48 (1H, dtd, J3β,3α =
13.4 Hz, J3β,2β = 3.7 Hz, J3β,2α = 3.6 Hz, J3β,1β = 1.0 Hz, Hβ–3), 1.30 (1H, Hα–1, overlapped signal),
1.28 (1H, Hα–3, overlapped signal), 1.21 (3H, d, J16,15 = 7.0 Hz, Me-16), 1.19 (3H, d, J17,15 = 7.0 Hz,
Me-17), 1.06 (3H, s, Me-18), 0.97 (3H, s, Me-19). 13C NMR (CDCl3, 100 MHz, ppm): δ 185.21 (C-14, s);
179.70 (C-11, s); 168.13 (OAc-7α, s); 164.52 (C-7’, 6–OBzCl, s), 163.19 (C-7’, 12–OBzCl, s); 152.40 (C-9, s);
149.50 (C-12, s); 141.02 (C-4’, 12–OBzCl, s); 139.80 (C-13, s); 139.79 (C-4’, 6–OBzCl, s); 135.67 (C-8, s);
131.84 (C-2’ and C-6’, 12–OBzCl, d); 131.22 (C-2’ and C-6’, 6–OBzCl, d); 129.24 (C-3’ and C-5’, 12–OBzCl,
d); 128.88 (C-3’ and C-5’, 6–OBzCl, d); 128.14 (C-1’, 6–OBzCl, s); 126.36 (C-1’, 12–OBzCl, s); 68.72 (C-6,
d); 65.19 (C-7, d); 49.30 (C-5, d); 42.47 (C-3, t); 38.78 (C-10, s); 38.37 (C-1, t); 33.77 (C-4, s); 33.29 (C-18, q);
25.23 (C-15, d); 23.20 (C-19, q); 21.23 (C-20, q); 20.37 (C-16, q); 20.21 (C-17, q); 18.81 (C-2, t).
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RoyPr2 (6): Yellow rectangular plates, (EtOAc–n-pentane), 1H-NMR (CDCl3, 400 MHz, ppm): δ
5.68 (1H, dd, J7β,6α = 2.0 Hz, J7β,5α = 0.5 Hz, Hβ–7), 5.49 (1H, br dd, J6α,7β = 2.0 Hz, J6α,5α = 1.6
Hz, Hα–6), 3.09 (1H, sept, J15,16(17) = 7.1 Hz, H– 15), 2.66 (1H, dq, J2’A,2’B = 17.2 Hz, J2’A,3’ = 7.6 Hz,
H2’A–12), 2.61 (1H, dq, J2’B,2’A = 17.2 Hz, J2’B,3’ = 7.6 Hz, H2’B–12), 2.51 1H, (br d, J1α,1β = 12.4
Hz, Hβ–1), 2.32 (1H, dq, J2’A,2’B = 16.8 Hz, J2’A,3’ = 7.6 Hz, HA–2’), 2.25 (1H, q, J2’B,2’A = 16.8 Hz,
J2’B,3’ = 7.6 Hz, HB–2’), 2.04 (3H, s, OAc-7α), 1.77 (1H, dddt, J2β,2α = 14.4 Hz, J2β,1α = J2β,3α = 13.8
Hz, J2β,1β = J2β,3β = 3.6 Hz, Hβ–2), 1.59 (3H, s, Me-20), 1.55 (1H, dquint, J2α,2β = 14.4 Hz, J2α,1α =
J2α,1β = J2α,3α = J2α,3β = 3.6 Hz, Hα–2), 1.53 (1H, dd, J5α,6α = 1.6 Hz, J5α,7β = 0.5 Hz, Hα–5), 1.44
(1H, dtd, J3β,3α = 13.8 Hz, J3β,2α = J3β,2β = 3.6 Hz, J1β,3β = 1.6 Hz, Hβ–3), 1.27 (3H, t, J3”,2”A =
J3”,2”B = 7.6 Hz, Me-3”), 1.24 (1H, Hα–1, overlapped signal), 1.23 (1H, Hα–3, overlapped signal), 1.17
(3H, d, J16,15 = 7.1 Hz, Me- 16), 1.16 (3H, d, J17,15 = 7.1 Hz, Me-17), 1.11 (1H, t, J3’,2’A = J3’,2’B = 7.6
Hz, H-3’), 0.98 (3H, s, Me-18), 0.96 (3H, s, Me-19); 13C NMR (CDCl3, 100 MHz, ppm): δ 185.37 (C-14, s);
179.67 (C-11, s); 172.50 (C-1’, s); 171.73 (C-1”, s), 168.15 (OAc-7α, s); 152.22 (C-9, s); 149.28 (C-12, s);
139.42 (C-13, s); 135.67 (C-8, s); 67.24 (C-6, d); 65.25 (C-7, d); 48.95 (C-5, d); 42.39 (C-3, t); 38.93 (C-10, s);
38.31 (C-1, t); 33.58 (C-4, s); 33.18 (C-18, q); 27.81 (C-2’, t), 27.21 (C-2”, t); 25.17 (C- 15, d); 23.03 (C-19,
q); 21.44 (C-20, q); 21.27 (OAc-7α, q); 20.17 (C-16, q); 20.19 (C-17, q); 18.78 (C-2, t), 8.86 (C-3”, q); 8.80
(C-3’, q).
DihydroxyRoy (7): Yellow needles, 1H NMR (CDCl3, 400 MHz, ppm): δ 7.27 (1H, s, OH-12), 7.25
(1H, s, OH-6β), 4.51 (1H, dd, J = 3.3 Hz, J7β,6α = 2.0 Hz, H-7β), 4.45 (1H, dd, J6α,5α = 4.0 Hz, J6α,7β
= 2.0 Hz, H-6α), 3.16 (1H, sept, J15,16(17) = 7.1 Hz, H-15), 2.93 (1H, d, JOH,7β = 3.3 Hz, OH-7α), 2.59
(1H, dddd, J1β,1α = 12.8 Hz, J1β,2α = 3.5 Hz, J1β,2β = 3.5 Hz, J1β,3β(W) = 1.3 Hz, H-1β), 1.83 (1H,
ddddd, J2β,1α = 13.4 Hz, J2β,1β = 3.5 Hz, J2β,2α = 13.9 Hz, J2β,3α = 13.4 Hz, J2β,3β = 3.4 Hz, H-2β),
1.60 (3H, s, Me-20), ~1.56 (1H, J2α,1α = 3.8 Hz, J2α,1β = 3.5 Hz, J2α,2β = 13.9 Hz, J2α,3α = 4.1 Hz,
J2α,3β = 3.4 Hz, H-2α, overlapped signal), 1.47 (1H, dddd, J3,2α = 3.4 Hz, J3β,2β = 3.4 Hz, J3β,3α
= 13.4 Hz, J3β(W),1β = 1.3 Hz, H-3β), 1.40 (1H, d, J5α,6α = 4.0 Hz, H-5α), 1.25 (3H, s, Me-19), 1.22
(1H, ddd, J3α,2α = 4.1 Hz, J3α,2β = 13.4 Hz, J3α,3β = 13.4 Hz, H-3α), 1.22 (3H, d, J16(17),15 = 7.1 Hz,
Me-16), 1.21 (3H, d, J17,15 = 7.1 Hz, Me-17), 1.18 (1H, ddd, J1α,1β = 12.8 Hz, J1α,2α = 3.8 Hz, J1α,2β =
13.4 Hz, H-1α), 1.04 (3H, s, Me-18). 13C NMR (100 MHz, CDCl3, ppm): δ 38.5 (C-1, t); 19.0 (C-2, t); 42.3
(C-3, t); 33.8 (C-4, s); 49.5 (C-5, d); 69.4 (C-6, d); 69.2 (C-7, d); 141.0 (C-8, s); 147.5 (C-9, s); 38.6 (C-10, s);
183.5 (C-11, s); 151.1 (C-12, s); 124.3 (C-13, s); 189.1 (C-14, s); 24.3 (C-15, d); 19.9# (C-16, q); 19.8# (C-17,
q); 33.5 (C-18, q); 24.0 (C-19, q); 21.6 (C-20, q).
4.2. Cytotoxicity Assay
In order to screen the cytotoxicity of the isolated compounds 1-3, three breast cancer cell lines
representing three major classes of breast cancer were selected: MCF-7 cell line expressing estrogen
receptors, SkBr3 expressing high levels of Her2NEU, and SUM159 cell line negative for both hormone
receptors and for Her2. The named cell lines were cultivated in DMEM with 10% fetal calf serum.
Additionally, SUM159 cells were also cultivated under cancer stem cell-inducing conditions in special
media with 10 ng/mL basic fibroblast growth factor (bFGF), 20 ng/mL epidermal growth factor (EGF),
5 µg/mL insulin (all three from Peprotech, New York, USA), and 20 µL/mL B27 supplement (Invitrogen),
and are referred to as SUM159 sphere.
4.3. Cell Viability Assay
Cells grow in this media from spheres and increase the number of cells expressing markers
of cancer stem cells CD44+/CD24-/ESAlow. All cell lines were cultivated at 37 ◦C in a humidified
atmosphere with 5% CO2. For the MTT viability assay, cells were harvested, counted, and seeded
at 10,000 cells/well. Cells were left for 24h to attach and then were treated with 1, 10, and 100 µM
solutions of 1, 2, and 3. Cells were left for 24 h and then were assayed for viability with the EZ4U MTT
assay (Biomedica, Austria) according to manufacturer’s instructions. Briefly, 20 µL of colorless dye
was added to each well. Mitochondria of the living cells oxidize the dye to a yellow-colored formazan
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derivative, which is then assayed on the plate reader at 450 nm with a reference wavelength of 620 nm.
All experiments were performed in biological duplicate and technical triplicates and were expressed as
mean ± SDs. Statistical analysis between groups was performed by two-way ANOVA with Tukey’s
multiple comparisons test. p values < 0.05 were considered statistically significant. Statistical analyses
were performed using the GraphPrism 7.0 software [43].
4.4. Ligands
The structure for the ligands was drawn in ChemDraw 17.0 [44] and converted to structure mol
files, energy minimized with MacroModel [45], with two different conformers generated for 2: One with
the terminal cyclohexane ring in the chair conformation, another with the terminal cyclohexane ring in
the half-chair conformation. The chair ring conformation was kept for further studies giving better
results than the other conformer. Ligands phorbol 12-myristate 13-acetate (PMA) and arachidonic acid
(ARA) were also used as controls. For docking in AutoDock Vina [46], ligands were prepared in ADT
Tools 1.5.6 [47].
4.5. Sequence Alignment
The protein sequences for PKC isoforms α, β, i, δ, ε, ζ, ι, and θwere downloaded from the Uniprot
database [48] and aligned with Clustal 2.1 [49].
4.6. Docking
Two programs with different scoring functions and optimization algorithms were used: AutoDock
Vina [46] and Glide XP (extra precision) v2018-2 [50] with Molecular Mechanics Generalize Born/Surface
Area (MMGBSA) post-processing. The protein crystal structures of human PKC isoforms α, β, ι, and θ,
with codes 4RA4, 2I0E, 3ZH8, and 5F9E, respectively, were downloaded from RCSB Protein Data
Bank [37] and preprocessed with ADT Tools 1.5.6 for calculating protonation states and to add hydrogen
atoms [47]. Crystallographic waters were not included in the structures for docking. The co-crystallized
ligands were also self-docked into their respective binding sites in order to calculate a reference value
for a positive control for the docking calculations.
4.7. Vina
The grid box with dimensions 24 × 24 × 24 Å was set in the center of the protein binding site,
spanning all the amino acid residues involved in binding based on the coordinates of co-crystalized
ligands. The exhaustiveness was set to 50. Ten runs were made for each docking calculation.
4.8. Glide
An inner grid box with a size of 25 Å per side was used as in previous procedures [51–53]. The extra
precision XP scoring function was employed. Parameter LIG_VCUT was set to 0.8 (default value) to
scale ligand van der Waals radii by 80% for those atoms with a partial charge smaller than 0.15 in order
to reduce steric clashes with the protein. The Virtual Screening protocol included a first screen with
HTVS, retaining all good-scoring poses, through to scoring with SP, again retaining all good-scoring
poses, then docking with the XP (extra precision) scoring function, and final post-processing by
calculating the MMGBSA energies for the final binding poses.
5. Conclusions
Subtle changes in the binding site of each PKC isoform change the predicted interaction profiles
of the ligands. Subtle changes in the royleanone substitution patterns, such as a double substitution
only with non-substituted phenyls, can increase certain predicted subtype specificity as is seen in the
increased interaction score with PKCδ isoform for RoyBz (4). On the other hand, a hydroxybenzoate
substituent on position four of the royleanone core can provide a better binding pose in PKCι, as seen for
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ParvD (3),. DeRoy (1) and ParvD (3) are the strongest predicted binders to all isoforms computationally
and to all breast cancer types experimentally, perhaps due to their interaction with the conserved Lys
in the catalytic site. They may also interact with hydrophobic residues in the hydrophobic motif of
atypical PKCs (isoform ι/λ/PKMζ), which may grant specificity to those isoforms. Their relatively small
size and deep and low exposure to solvent when in their bound conformation may indicate binding
advantages over other compounds. ParvD (3) has the strongest predicted interaction profile for all
isoforms. Studying the predicted structure–activity relationships, such as those between promising
royleanone compounds and different subtypes of PKC and types of cancer cells, such as the hard to
treat triple-negative cancer stem cells or tumor-initiating cells, can provide further indications to guide
the design of compounds that can inhibit particular PKC subtypes, or all of them, as well as being
active against aggressive triple-negative cancer cells. An interesting new compound for all isoforms
can be proposed by substituting a hydroxybenzoate on position four of the royleanone core of DeRoy
(1). Perhaps, the introduction of benzoate groups of the type in RoyBz (4) onto other royleanones may
increase the specificity for PKCδ.
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